Page last updated: 2024-10-22

anastrozole and ER-Negative PR-Negative HER2-Negative Breast Cancer

anastrozole has been researched along with ER-Negative PR-Negative HER2-Negative Breast Cancer in 1 studies

Research Excerpts

ExcerptRelevanceReference
"Premenopausal patients with breast cancer and more than 10 positive axillary nodes (BC>10) have a poor prognosis: In these patients the best adjuvant therapy (CT) has not yet been established."1.42Adjuvant Ovarian Suppression, High-dose Chemotherapy and Immunotherapy for Premenopausal Patients with High-risk Breast Cancer. ( Bratta, M; Candeloro, G; D'Orazi, V; Fumagalli, LA; Pasta, V; Rea, S; Recchia, F; Rosselli, M, 2015)

Research

Studies (1)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's0 (0.00)29.6817
2010's1 (100.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Recchia, F1
Candeloro, G1
Rosselli, M1
Bratta, M1
Pasta, V1
D'Orazi, V1
Fumagalli, LA1
Rea, S1

Other Studies

1 other study available for anastrozole and ER-Negative PR-Negative HER2-Negative Breast Cancer

ArticleYear
Adjuvant Ovarian Suppression, High-dose Chemotherapy and Immunotherapy for Premenopausal Patients with High-risk Breast Cancer.
    Anticancer research, 2015, Volume: 35, Issue:12

    Topics: Adult; Anastrozole; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols;

2015